| Document |
Document Title |
|
WO/2020/257794A3 |
The presently disclosed subject matter provides high-throughput assays, e.g, yeast three-hybrid assays, for detecting the presence of a molecule, e.g, therapeutic molecule. In certain embodiments, the presently disclosed subject matter p...
|
|
WO/2021/009247A1 |
The present invention relates to a method for modifying a target site in a host cell comprising contacting said host cell with a Cas nuclease, wherein said host cell is further contacted with a low-affinity Cas inhibitor and/or a sub-inh...
|
|
WO/2021/010898A1 |
Methods for the treatment and prevention of laminopathies and diseases characterised by hyperlipidemia through LING complex inhibition are disclosed. In particular, LING complex disruption by expression of dominant-negative LING complex ...
|
|
WO/2021/007612A1 |
The present invention relates to methods of producing recombinant plasminogen in a mammalian expression system. A method for producing plasminogen, the method comprising (i) providing a host cell comprising a first recombinant polynucleo...
|
|
WO/2021/007629A1 |
The present invention relates to a method for producing an enzyme cocktail that possesses cellulase activity from an improved culture medium, said method allowing for on-site production and ensuring enzyme production sustainability and e...
|
|
WO/2021/011524A1 |
The present disclosure relates to compositions and methods that enable enhanced monitoring and improvement of heterologous ribosome activity within a host cell. Specifically, the instant disclosure provides a reporter system that allows ...
|
|
WO/2021/007654A1 |
The present disclosure provides antisense oligonucleotides, compositions, and methods that target a ABCA4 exon or intron flanking an exon, thereby modulating splicing of ABCA4 pre-mRNA to increase the level of wild type ABCA4 mRNA molecu...
|
|
WO/2021/010341A1 |
The production method according to the present disclosure is for producing an organism-derived substance having introduced therein a bioactive substance, the production method including a step for causing a suspension including the bioac...
|
|
WO/2021/009030A1 |
The invention relates to a method for the enhancement of the transduction of a target cells by a viral vector using a cationic block-copolymer introduced as an additive alone or formulated with nanoparticles. The method comprises a step ...
|
|
WO/2021/008805A1 |
Presented are methods and compositions for using immobilized CRISPR/Cas9 enzymes for generating an immobilized library of randomly fragmented, double-stranded target nucleic acid fragments on a surface. The methods are useful for generat...
|
|
WO/2020/050602A9 |
The present invention pertains to: a recombination expression vector for screening cartilage disease treatment agents; a cell line transformed using the expression vector; and a method for using the same to screen drugs that are effectiv...
|
|
WO/2021/009993A1 |
A genetically modified nonhuman animal in which degradation of a target protein in a living body is controlled by the auxin degron system, said nonhuman animal having a chromosome including a first nucleic acid that codes for a mutant TI...
|
|
WO/2021/011803A1 |
Nucleic acid compositions having nucleotide sequences that do not occur in nature are provided. Also provided are populations of different nucleic acids having universal adapters or universal primer binding sites. Methods of capturing, c...
|
|
WO/2021/009633A1 |
Disclosed herein are synthetic chromatin vaccines (SCV) and compositions, including pharmaceutical compositions comprising such. Specifically, the disclosure provides a SCV comprising nucleosomes comprising an amino acid sequence of at l...
|
|
WO/2021/008577A1 |
The present invention relates to an anti-CD47/anti-CTLA-4 bispecific antibody and a preparation method therefor and an application thereof. The bispecific antibody comprises (a) a first antigen-binding portion, comprising a heavy chain v...
|
|
WO/2021/011348A1 |
The invention provides plants and seeds with enhanced resistance to plant disease caused by plant pathogens, particularly bacterial plant pathogens, and methods for producing such plants and seeds. The plants and seeds comprise mutated a...
|
|
WO/2021/010446A1 |
The present invention relates to a method for detecting a macrolide-antibiotic-resistant mutant bacterium, which comprises detecting two adenine point mutations, to each of which a macrolide antibiotic can bind, in a V-region in 23SrRNA ...
|
|
WO/2021/011353A1 |
Provided are activatable proprotein homodimers, comprising at least two separate polypeptide chains, each chain comprising an IL-2 protein, a cleavable linker, and an IL-2 binding protein, among other optional features, and related pharm...
|
|
WO/2021/009242A1 |
The invention relates to a hybrid DNA/RNA molecule, to the complex thereof with at least one nanoparticle and to the use of this complex for the prevention or treatment of a disease, in particular a disease of the digestive system.
|
|
WO/2021/011842A1 |
The present application discloses methods for synthetic production and cell-free synthesis of single stranded adeno-associated virus (AAV) vectors, for delivery and expression of a transgene in host cells. The present invention also rela...
|
|
WO/2021/011474A1 |
Provided herein are thermomer monomer, thermomer dimers, thermomer monomeric constructs, thermomer dimeric complexes, and related gene expression cassette vectors, cells, surfaces devices, compositions methods and systems, that provide a...
|
|
WO/2021/011840A1 |
The present application discloses methods for synthetic production and cell-free synthesis of DNA vectors, particularly closed-ended linear DNA vectors having one or more gaps (e.g., nicked ceDNA vectors, "neDNA") and adenoassociated-vir...
|
|
WO/2021/010264A1 |
Provided is a means for increasing mannosylerythritol lipid (MEL) production efficiency. The present invention is a mannosylerythritol lipid-producing microorganism transformed by an expression vector having a gene that encodes a lipase ...
|
|
WO/2021/010481A1 |
The present invention provides a novel polypeptide. The polypeptide found by the inventors of the present invention does not have self-cohesive properties and has adhesive properties. The adhesive polypeptide according to the present inv...
|
|
WO/2021/011827A1 |
The present disclosure provides recombinant ly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide ...
|
|
WO/2021/011648A2 |
The present disclosure provides, in part, nucleic acid loaded flowable hydrogels and compositions, systems and methods related thereto, to effectively deliver nucleic acids to cells that contact the flowable hydrogels.
|
|
WO/2021/011216A2 |
The invention provides recombinant DNA molecules comprising novel synthetic Intergenic Sequence Regions for use in plants to reduce the interaction of a first transgene expression cassette on a second transgene cassette when inserted bet...
|
|
WO/2021/011941A1 |
The present invention is directed to methods for increasing the efficiencies with which recombinant adeno-associated virus (rAAV) are packaged, so as to increase their production titers. More specifically, the invention relates to a meth...
|
|
WO/2021/009990A1 |
An auxin-inducible degron system kit that regulates the degradation of a target protein in an eukaryotic cell derived from a non-plant, said kit comprising: a first nucleic acid encoding a mutant TIR1 family protein having a mutation at ...
|
|
WO/2021/009701A1 |
The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a ...
|
|
WO/2021/007647A1 |
A method of engineering bacteriophages comprising isolating a bacteriophage; removing all attachment genes from a genome of said bacteriophage; inserting a first unique open reading frame encoding one or more attachment genes and inserti...
|
|
WO/2021/008308A1 |
A fusion protein and composition for treating animal tumors. The fusion protein comprises three different gene segments. The fusion protein has a good inhibitory effect on various animal solid tumors, and is capable of shrinking tumors, ...
|
|
WO/2021/009694A1 |
The invention relates to an in vivo functional ligands (IFLs) including a single-chain variable fragment (scFv) domain, a fragment crystalIizable (Fc) domain, and a hinge domain joining the scFv and Fc domains. The IFLs specifically bind...
|
|
WO/2020/243490A3 |
The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.
|
|
WO/2021/009684A1 |
The invention relates to recombinant adeno-associated virus (rAAV) virions for gene therapy, wherein the rAAV virions comprise a novel capsid protein. In particular, the invention relates to the use of such virions in gene therapy for th...
|
|
WO/2021/011649A2 |
Provided herein are methods and agents for gene specific demethylation and/or activation. Oligonucleotide constructs are provided, the oligonucleotide constructs including: [1] a targeting portion having sequence complementarity and bind...
|
|
WO/2021/011619A1 |
The present invention is directed to novel nucleotide sequences of Senecavirus A ("SVA"), including novel genotypes thereof, which are useful as live attenuated and other vaccine compositions for treating and preventing diseases in swine...
|
|
WO/2021/011829A1 |
The invention relates, in part, to methods and systems with which to identify guide RNAs (gRNAs) and methods and systems with which to prepare, design, and generate gRNAs and minimally repetitive arrays of gRNAs.
|
|
WO/2021/010239A1 |
The present invention pertains to a method for detecting an RNA virus by reverse transcription-polymerase chain reaction (RT-PCR) and a kit for carrying out the method. More specifically, the present invention pertains to a method for de...
|
|
WO/2021/008463A1 |
Provided are a CLDN18.2-combined antibody and an unfucosylated form thereof. Further provided are a preparation method for the antibody, a conjugate and a composition containing the antibody, and use thereof in the treatment of a disease...
|
|
WO/2021/010268A1 |
Provided is a method for producing an N-substituted amide compound/amide compound copolymer using a biocatalyst, the method comprising: (A) a step for reacting an amide compound with an amine in the presence of an enzyme that catalyzes a...
|
|
WO/2021/008447A1 |
Provided are methods for editing RNA by introducing a deaminase-recruiting RNA in a host cell for deamination of an adenosine in a target RNA, deaminase-recruiting RNAs used in the RNA editing methods, compositions and kits comprising th...
|
|
WO/2021/010303A1 |
Provided is a novel therapeutic agent for a disease caused by a dominant mutant gene (7). The therapeutic agent according to the present invention comprises a donor DNA (20) that contains a polynucleotide having the following sequences (...
|
|
WO/2021/011781A1 |
In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for engineering immune effector cells, e.g., T cells, NK cells, monocytes and/or macrophages to recognize and destroy a desir...
|
|
WO/2021/008523A1 |
Provided are antibodies that bind specifically to TIGIT or antigen binding fragments of the antibodies and a composition thereof. Also provided are a nucleic acid molecule coding the antibodies or the antigen binding fragments thereof, a...
|
|
WO/2021/009126A1 |
The invention concerns a double-stranded (ds) ribonucleic acid (RNA) comprising a sense strand and an antisense strand, wherein: the sense strand comprises the nucleotide sequence SEQ ID NO: 1 and the antisense strand comprises the nucle...
|
|
WO/2021/011841A1 |
The present disclosure provides novel vectors and methods useful in treating genetic diseases, brain disorders, and neurological diseases and disorders, including gene therapy vectors and methods of administering such to a subject in nee...
|
|
WO/2021/008267A1 |
Provided are a virus and a tumor therapeutic drug for specifically killing tumor cells The virus is a recombinant oncolytic virus, and the genome thereof has an exogenous promoter which is located upstream of an essential gene of the vir...
|
|
WO/2021/010346A1 |
Provided are: an antibody which specifically binds to and neutralizes USAG-1 or an antigen-binding fragment thereof; and a pharmaceutical composition containing the antibody or the antigen-binding fragment.
|
|
WO/2021/011365A1 |
The invention relates to the delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity to liver, nervous system and/or intestine resulting in enhanced clearance of cell free DNA (cfDNA) useful for treatment o...
|
